Succesfully treated Curvularia lunata peritonitis in a peritoneal dialysis patient

Kalawat, Usha; Reddy, G. Obul; Sandeep, Yanala; Naveen, P; Yadla, Manjusha; Chaudhury, Abhijit; Kumar, V Siva

doi:10.4103/0971-4065.101269

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous successes with triazole antifungal agents (itraconazole, voriconazole) for treatment of IFDs caused by Curvularia have been reported, and the patient with pulmonary and skin IFDs caused by Curvularia lunata in the current study (Patient 14) ultimately responded to isavuconazole after 52 days of treatment. That patient had previously failed to respond to treatment regimens that included amphotericin B, voriconazole and posaconazole.…”

Section: Discussionmentioning

confidence: 59%

Isavuconazole for treatment of rare invasive fungal diseases

Cornely

Mullane

Ostrosky-Zeichner

et al. 2018

Mycoses

View full text Add to dashboard Cite

Data regarding treatment of rare invasive fungal diseases (IFDs) are scarce. We documented the efficacy and safety of isavuconazole for treatment of uncommonly diagnosed IFDs. VITAL was a single-arm, international, open-label study evaluating the efficacy and safety of isavuconazole (200 mg orally or intravenously every 8 hours for 48 hours, then once daily). The primary outcome was overall response at Day 42; key secondary outcomes were overall responses at Day 84 and end of treatment (EOT), mortality at Days 42 and 84, and safety. This analysis includes patients with IFD caused by rare or unidentified pathogens. Twenty-six patients with IFDs caused by rare moulds (n = 17), non-Candida yeasts (n = 2), or unidentified moulds (n = 7) were enrolled (median treatment duration [range], 114.5 [1-496]) days. Overall treatment success was observed in 11/26 (42.3%), 10/26 (38.5%), and 15/26 (57.7%) patients at Days 42, 84, and EOT, respectively. All-cause mortality rates were 2/26 patients (7.7%) at Day 42 and 4/26 patients (15.4%) at Day 84; another two patients died after Day 84. All patients had ≥1 treatment-emergent adverse event (TEAE); 15 patients (57.7%) had serious TEAEs, and TEAEs led to discontinuation of isavuconazole in four patients (15.4%). Isavuconazole may be efficacious for treatment of a range of rare IFDs.

show abstract

Section: Discussionmentioning

confidence: 59%

Isavuconazole for treatment of rare invasive fungal diseases

Cornely

Mullane

Ostrosky-Zeichner

et al. 2018

Mycoses

View full text Add to dashboard Cite

show abstract

Uncommon Yeasts and Molds Causing Human Disease

Shoff

Perfect

2021

Encyclopedia of Mycology

View full text Add to dashboard Cite

Tubo-ovarian mass with raised CA-125 in a 21-year-old female

et al. 2022

View full text Add to dashboard Cite

Introduction Peritonitis associated with fungal species Curvularia lunata seldom occurs with only five cases reported in the literature, all in middle-age patients with comorbidities undergoing dialysis. Case report A 21-year-old female who was referred to surgical oncology OPD with a diagnosis of ovarian malignancy, based on raised cancer antigen 125 (CA 125) and suspected tubo-ovarian mass (TOM) on magnetic resonance imaging (MRI). A review of the MRI showed a pelvic collection with TOM, suggestive of infective pathology. Fungal culture and mass spectroscopy of the cystic collection identified the presence of Curvularia lunata. She was treated with oral itraconazole which showed symptomatic improvement and radiological response. In the follow-up period, the patient developed chest wall swelling, aspiration and geneXpert® revealed multidrug-resistant (MDR) tuberculosis, and treatment was started. Conclusions Unusual causes of TOM and raised CA 125 should be kept in mind when dealing with young patients, as the possibility of epithelial ovarian cancer in this age is very low.

show abstract

Succesfully treated Curvularia lunata peritonitis in a peritoneal dialysis patient

Cited by 3 publications

References 4 publications

Isavuconazole for treatment of rare invasive fungal diseases

Isavuconazole for treatment of rare invasive fungal diseases

Uncommon Yeasts and Molds Causing Human Disease

Tubo-ovarian mass with raised CA-125 in a 21-year-old female

Contact Info

Product

Resources

About